Discontinuation of Sublocade from the NSW Opioid Treatment Program

​There are currently two medication options for long-acting injectable buprenorphine (LAIB) in the NSW Opioid Treatment Program (OTP), Buvidal (weekly or monthly injections) and Sublocade (monthly injections), which provide extended-release buprenorphine as an alternate treatment to daily methadone or sublingual buprenorphine.

The manufacturer of Sublocade (Indivior) has made the commercial decision to discontinue supply of Sublocade to Australia from 31 December 2026. This decision is not related to evidence of safety or efficacy concerns.

 

 

Below are some key dates regarding ordering and final PBS claims

  • Stock will remain available and final orders will be accepted until 11 December 2026 to support patient care.
  • PBS claims for Sublocade may be made until 31 December 2026, subject to applicable PBS requirements

Indivior have advised that anyone with remaining Sublocade stock will be refunded.


​Information and support

For patients:

  • Changes to Sublocade Availability in Australia
  • Contact your prescriber or any member of your treatment team as soon as you can
  • NUAA's Peerline is available Monday to Friday, 9am-5pm. Phone: 1800 644 413 or email peerline@nuaa.org.au to connect with a friendly peer.
  • The NSW Opioid Treatment line is available 9:30am-5pm, 7 days a week (not public holidays). Phone: 1800 642 428

For health professionals:

  • Guidance for Transferring from Sublocade to other Opioid Dependence Treatment Medications or Completing Treatment - coming soon
  • Guidance for Community Pharmacists - coming soon
  • Drug and Alcohol Specialist Advisory Service (DASAS) can also offer further advice on the clinical management of transferring between ODT medicines through its free 24-hour telephone service. Phone: 1800 023 687
  • Pharmacist to Pharmacist advice line. Phone: 1300 369 772 (8:30am-5:00pm weekdays)
Current as at: Wednesday 1 July 2026
Contact page owner: Centre for Alcohol and Other Drugs